Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.73 |
| ▸ | MAPK12 | P53778 | 18/20 | 0.73 |
| ▸ | HCK | P08631 | 17/20 | 0.73 |
| ▸ | SRC | P12931 | 3/20 | 0.71 |
| ▸ | SYK | P43405 | 1/20 | 0.67 |
| ▸ | GSK3A | P49840 | 1/20 | 0.67 |
| ▸ | GSK3B | P49841 | 1/20 | 0.67 |
| ▸ | TNF | P01375 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13563511 | 0.94 | MAPK14 (0.74) | MAPK14MAPK12HCKSRCSYK | |
| SCHEMBL12540477 | 0.94 | MAPK14 (0.69) | MAPK14MAPK12HCKSRCSYK | |
| SCHEMBL12540123 | 0.93 | MAPK14 (0.86) | MAPK14MAPK12HCKSRCSYK | |
| SCHEMBL2532803 | 0.91 | MAPK14 (0.76) | MAPK14MAPK12HCKSRCTNF | |
| SCHEMBL2405918 | 0.86 | MAPK14 (0.75) | MAPK14MAPK12HCKSRCSYK | |
| SCHEMBL2530318 | 0.85 | MAPK14 (0.72) | MAPK14MAPK12HCKSRCSYK | |
| SCHEMBL12695287 | 0.85 | MAPK14 (1.00) | MAPK14MAPK12HCKSRCSYK | |
| SCHEMBL12278043 | 0.84 | MAPK14 (0.86) | MAPK14MAPK12HCKSRCTNF | |
| SCHEMBL2528112 | 0.84 | MAPK14 (0.74) | MAPK14MAPK12HCKSRCSYK | |
| SCHEMBL2573234 | 0.83 | MAPK14 (1.00) | MAPK14MAPK12HCKSRCTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370428-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2016-08-10 | — | — | EP | disclosed |
| US-8299073-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2012-10-30 | — | — | US | disclosed |
| US-20110294812-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2011-12-01 | — | — | US | disclosed |
| EP-2370428-A1 | P38 MAP KINASE INHIBITORS | Respivert Limited (GB) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010067131-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294812-A1 | P38 MAP KINASE INHIBITORS | MAPK1, MAP3K1, MAPK3 | MAPK14 10/4885MAPK12 13/4885HCK 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.